KN 018

Drug Profile

KN 018

Alternative Names: KN-018

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator Alphamab
  • Class
  • Mechanism of Action CD80 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 13 Jul 2016 KN 018 is available for licensing as of 07 May 2015. http://www.alphamab.com/
  • 07 May 2015 Preclinical trials in Autoimmune disorders in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top